AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Delivers robust earnings performance, successfully navigating a dynamic environment
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Bayer expects 2025 to be the most difficult year of its turnaround
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
A new weapon in the global fight against malaria
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Subscribe To Our Newsletter & Stay Updated